

1 IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

2 Applicant: E.A. Wayner

Attorney Docket No. CYTE16162

3 Serial No: 07/814,873

Group Art Unit: 1806

4 Filed: December 24, 1991

Examiner: Phillip D. Gambel, Ph.D.

5 Title: INHIBITION OF LYMPHOCYTE ADHERENCE TO VASCULAR ENDOTHELIUM

6 DECLARATION BY ASSIGNEE

7 Seattle, Washington 98101

8 TO THE COMMISSIONER OF PATENTS AND TRADEMARKS:

9 Fred Hutchinson Cancer Research Center, the owner by unrecorded assignment of the
10 above-entitled patent application, declares and states as follows:

11 The cell lines designated as P3E3, P4G9, P4C10, and P4C2 in the above-identified patent
12 application were deposited on September 1, 1989, at the American Type Culture Collection, 12301
13 Parklawn Drive, Rockville, MD 20852, under ATCC accession numbers HB 10212, HB 10213, HB
14 10214, and HB 10215, respectively. A copy of the Budapest Treaty Receipt is attached hereto.

15 Fred Hutchinson Cancer Research Center hereby assures that all restrictions imposed by the
16 depositor on the availability to the public of the deposited materials will be irrevocably removed upon
17 the granting of a patent.

18 ///

19 ///

20 ///

21 ///

22 ///

23 ///


24 ///

25 ///

1 Further, that all statements made herein of our knowledge are true, that all statements made
2 on information and belief are believed to be true, and that the statements were made with the
3 knowledge that willful false statements and the like so made are punishable by fine or imprisonment,
4 or both, under Section 1001 of Title 18 of the United States Code, and that such willful false
5 statements may jeopardize the validity of any patent issuing from the above-identified patent
6 application.

7 FRED HUTCHINSON CANCER
8 RESEARCH CENTER

9
10
11 Date: October 25, 1993

12 By 
13 Catherine J. Hennings
14 Manager, Technology Transfer

15 TFB/mhk/daf
16
17
18
19
20
21
22
23
24
25